LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Recommendation of “Moderate Buy” from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $100.20.

A number of analysts have commented on the stock. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Roth Mkm restated a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Finally, Wells Fargo & Company decreased their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after acquiring an additional 21,946 shares during the period. First Trust Advisors LP lifted its stake in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after purchasing an additional 111,193 shares during the last quarter. Geneva Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 6.0% during the 2nd quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock worth $76,010,000 after purchasing an additional 51,489 shares during the period. State Street Corp increased its position in shares of LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after purchasing an additional 6,130 shares during the last quarter. Finally, Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 5.8% in the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Trading Up 1.2%

LeMaitre Vascular stock opened at $87.66 on Friday. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $105.55. The company has a market cap of $1.99 billion, a P/E ratio of 37.78, a P/E/G ratio of 1.92 and a beta of 0.72. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $84.83 and a two-hundred day simple moving average of $87.86.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.